Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Int J Oral Maxillofac Surg ; 43(2): 156-62, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24100154

RESUMO

A navigation-assisted multidisciplinary network to improve the interface between radiology, surgery, radiotherapy, and pathology in the field of head and neck cancer is described. All implicated fields are integrated by a common server platform and have remote data access in a ready-to-use format. The margins of resection and exact locations of biopsies are mapped intraoperatively. The pathologist uses the numerical coordinates of these samples to precisely trace each specimen in the anatomical field. Subsequently, map-guided radiotherapy is planned. In addition to the benefits of image-guided resection, this model enables radiotherapy planning according to the specific coordinates of the resection defect plus any residually affected sites identified by the pathologist. Irradiation of adjacent healthy structures is thereby minimized. In summary, the navigation-assisted network described grants timely multidisciplinary feedback between all fields involved, attains meticulous pathological definition, and permits optimized coordinate-directed radiotherapy.


Assuntos
Redes de Comunicação de Computadores , Diagnóstico por Imagem , Neoplasias de Cabeça e Pescoço/cirurgia , Planejamento da Radioterapia Assistida por Computador , Cirurgia Assistida por Computador , Interface Usuário-Computador , Neoplasias de Cabeça e Pescoço/diagnóstico , Neoplasias de Cabeça e Pescoço/patologia , Neoplasias de Cabeça e Pescoço/radioterapia , Humanos , Processamento de Imagem Assistida por Computador , Imageamento Tridimensional , Software
2.
Br J Cancer ; 94(8): 1099-106, 2006 Apr 24.
Artigo em Inglês | MEDLINE | ID: mdl-16622435

RESUMO

The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled) underwent tumour resection after three 3-week cycles of docetaxel 85 mg m-2 (day 1) plus cisplatin 40 or 50 mg m-2 (days 1 and 2). Therapy was well tolerated (overall grade 3 toxicity occurred in 48% patients; no grade 4 nonhaematological toxicity was reported), with no observed late toxicities. Median overall survival (OS) and event-free survival (EFS) times were 35 and 15 months, respectively, in the 75 patients who underwent surgery; corresponding figures for all 90 patients enrolled were 28 and 12 months. At 3 years after initiating trial therapy, 27 out of 75 patients (36%) were alive and tumour free. At 5-year follow-up, 60 and 65% of patients had local relapse and distant metastases, respectively. The most common sites of distant metastases were the lung (24%) and brain (17%). Factors associated with OS, EFS and risk of local relapse and distant metastases were complete tumour resection and chemotherapy activity (clinical response, pathologic response, mediastinal downstaging). Neoadjuvant docetaxel-cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/cirurgia , Neoplasias Pulmonares/cirurgia , Adulto , Idoso , Carcinoma Pulmonar de Células não Pequenas/diagnóstico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Quimioterapia Adjuvante , Cisplatino/uso terapêutico , Terapia Combinada , Intervalo Livre de Doença , Docetaxel , Feminino , Seguimentos , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Estadiamento de Neoplasias , Prognóstico , Recidiva , Medição de Risco , Taxa de Sobrevida , Taxoides/uso terapêutico , Fatores de Tempo , Resultado do Tratamento
3.
Ann Thorac Surg ; 69(5): 1550-5, 2000 May.
Artigo em Inglês | MEDLINE | ID: mdl-10881840

RESUMO

BACKGROUND: To compare the prognostic relevance of Masaoka and Müller-Hermelink classifications. METHODS: We treated 71 patients with thymic tumors at our institution between 1980 and 1997. Complete follow-up was achieved in 69 patients (97%) with a mean follow up-time of 8.3 years (range, 9 months to 17 years). RESULTS: Masaoka stage I was found in 31 patients (44.9%), stage II in 17 (24.6%), stage III in 19 (27.6%), and stage IV in 2 (2.9%). The 10-year overall survival rate was 83.5% for stage I, 100% for stage IIa, 58% for stage IIb, 44% for stage III, and 0% for stage IV. The disease-free survival rates were 100%, 70%, 40%, 38%, and 0%, respectively. Histologic classification according to Müller-Hermelink found medullary tumors in 7 patients (10.1%), mixed in 18 (26.1%), organoid in 14 (20.3%), cortical in 11 (15.9%), well-differentiated thymic carcinoma in 14 (20.3%), and endocrine carcinoma in 5 (7.3%), with 10-year overall survival rates of 100%, 75%, 92%, 87.5%, 30%, and 0%, respectively, and 10-year disease-free survival rates of 100%, 100%, 77%, 75%, 37%, and 0%, respectively. Medullary, mixed, and well-differentiated organoid tumors were correlated with stage I and II, and well-differentiated thymic carcinoma and endocrine carcinoma with stage III and IV (p < 0.001). Multivariate analysis showed age, gender, myasthenia gravis, and postoperative adjuvant therapy not to be significant predictors of overall and disease-free survival after complete resection, whereas the Müller-Hermelink and Masaoka classifications were independent significant predictors for overall (p < 0.05) and disease-free survival (p < 0.004; p < 0.0001). CONCLUSIONS: The consideration of staging and histology in thymic tumors has the potential to improve recurrence prediction and patient selection for combined treatment modalities.


Assuntos
Timoma/classificação , Timoma/mortalidade , Neoplasias do Timo/classificação , Neoplasias do Timo/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Intervalo Livre de Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Recidiva Local de Neoplasia , Prognóstico , Timoma/patologia , Timoma/cirurgia , Neoplasias do Timo/patologia , Neoplasias do Timo/cirurgia
4.
Ann Oncol ; 10(6): 677-83, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10442190

RESUMO

BACKGROUND: The upper limit of the natural decline in creatinine clearance is 1 ml/min/year. To define the loss of renal function, we started a long-term assessment of patients with ovarian cancer treated by whole abdominal irradiation (WAI) with preceding cisplatin chemotherapy (CDDP) and second-look laparotomy (SLL). PATIENTS AND METHODS: We analyzed the creatinine clearance over time of 56 patients treated from 1982 to 1988 for ovarian cancer. Thirty-one of 56 patients had received WAI after their initial surgery, and 25 of 56 patients had undergone CDDP therapy followed by SLL, and then WAI after their initial surgery. Median follow-up was 99 months (7-156). Twenty of 56 patients accepted our invitation for additional assessment of tubular function, nine of the 31 patients without CDDP therapy and SLL, and 11 of the 25 patients with CDDP followed by SLL and WAI. Ten of twenty patients had received four to six cycles CDDP, 80 mg/m2/cycle, and one patient nine cycles. The median total dose for each kidney was 1450 cGy (480-1690). RESULTS: The mean creatinine clearance decreased from 84 ml/min to 66 ml/min. Seventy-six percent of the 25 patients who had undergone CDDP therapy, SLL and WAI had declines of more than 1 ml/min/year, 64% of these patients of more than 2 ml/min/year. For the 31 patients who had received WAI after their initial surgery, the corresponding numbers were 71% and 55%, respectively. The tubular function of the 20 patients who had undergone the additional investigations was not impaired. CONCLUSION: The decline in renal function after WAI is more pronounced than in healthy subjects. The treatment with cisplatin and SLL prior to WAI does not seem to contribute to this loss of kidney function.


Assuntos
Antineoplásicos/uso terapêutico , Cisplatino/uso terapêutico , Rim/fisiopatologia , Neoplasias Ovarianas/radioterapia , Radioterapia/efeitos adversos , Abdome/efeitos da radiação , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/administração & dosagem , Cisplatino/administração & dosagem , Terapia Combinada , Creatinina/metabolismo , Feminino , Seguimentos , Taxa de Filtração Glomerular , Humanos , Rim/efeitos da radiação , Pessoa de Meia-Idade , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/fisiopatologia
6.
Ther Umsch ; 55(7): 399-401, 1998 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-9702102

RESUMO

Although surgeons are able to resect completely locally advanced non-small cell lung cancer with mediastinal lymph node involvement (stage IIIA), the majority of patients succumb from metastatic disease. Therefore, neoadjuvant therapy was introduced in the management of this disease in order to eradicate distant metastases at an early stage. Phase II trials with preoperative chemotherapy in stage IIIA patients have shown that the pathological response (amount of tumour necrosis) and the clearance of mediastinal lymph node correlate with a better survival and is the best predictor for eradication of distant metastases. Indeed, three small randomised phase III studies have demonstrated a survival advantage for preoperative chemotherapy compared to surgery alone. Further studies are required to determine the best neoadjuvant regimen inducing the largest amount of tumour necrosis.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma Pulmonar de Células não Pequenas/cirurgia , Quimioterapia Adjuvante , Ensaios Clínicos como Assunto , Terapia Combinada , Humanos , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/cirurgia , Estadiamento de Neoplasias , Taxa de Sobrevida
7.
Ther Umsch ; 55(7): 402-4, 1998 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-9702103

RESUMO

Radiation is a standard treatment for patients with locally advanced non-small cell lung cancer. Only 5% of patients are alive after 5 years. Improvement of local control and survival time have been yielded using knowledge in radiobiology and technical innovations, especially three dimensional planning on the basis of CT and MRI. Further improvement could be reached by performing combination of radio- and chemotherapy. However, the best sequence of chemo- and radiotherapy could not be defined yet.


Assuntos
Carcinoma Broncogênico/radioterapia , Carcinoma Pulmonar de Células não Pequenas/radioterapia , Neoplasias Pulmonares/radioterapia , Carcinoma Broncogênico/tratamento farmacológico , Carcinoma Broncogênico/mortalidade , Carcinoma Broncogênico/patologia , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Carcinoma Pulmonar de Células não Pequenas/patologia , Quimioterapia Adjuvante , Terapia Combinada , Seguimentos , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/patologia , Taxa de Sobrevida
8.
Strahlenther Onkol ; 174(6): 306-10, 1998 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-9645211

RESUMO

BACKGROUND: Patients with carcinomas of the upper aero-digestive tract often suffer from ear pain as a tumor associated syndrome. This prospective study examines the predictive and prognostic value of this symptom. PATIENTS AND METHODS: Ninety-six consecutive patients who completed a locally radiotherapy of a carcinoma of the oropharynx were prospectively evaluated and followed. Forty-nine out of 96 patients stated the symptom, either spontaneously or after questioning. The 2 groups showed no difference regarding TNM-classification, histology and total dose. Overall survival, local control and disease specific survival were calculated according to Kaplan-Meier and compared by the log-rank test. RESULTS: A clinically complete remission was obtained in significantly fewer patients with reflex-otalgia as compared to patients without reflex-otalgia, 61.2% versus 89.3%, p < 0.002. Local control of patients with reflex-otalgia was significantly less with 49%, mean follow-up 564 days, in comparison to local control in patients without reflex-otalgia, mean follow-up 613 days, p = 0.01. Disease specific survival was significantly worse for patients with reflex-otalgia, p < 0.012. The probability of local control of T1/T2 tumors with reflex-otalgia was similar to T3/T4 tumors without reflex-otalgia. Local control for all tumor categories combined is 74% for patients without reflex-otalgia versus 49% for patients with reflex-otalgia. CONCLUSION: In our patients, reflex-otalgia is a new and statistically significant parameter for the probability of local control and disease specific survival.


Assuntos
Carcinoma de Células Escamosas/radioterapia , Dor de Orelha/radioterapia , Neoplasias Orofaríngeas/radioterapia , Síndromes Paraneoplásicas/radioterapia , Reflexo Anormal/efeitos da radiação , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/patologia , Dor de Orelha/mortalidade , Dor de Orelha/patologia , Feminino , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias Orofaríngeas/mortalidade , Neoplasias Orofaríngeas/patologia , Síndromes Paraneoplásicas/mortalidade , Síndromes Paraneoplásicas/patologia , Prognóstico , Estudos Prospectivos , Radioterapia de Alta Energia , Análise de Sobrevida
9.
Br J Dermatol ; 134(4): 763-5, 1996 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8733388

RESUMO

Classic angiosarcoma is an uncommon malignant neoplasm of vascular differentiation which is highly aggressive. The diagnosis is often delayed and, since the response to treatment mainly depends on the size of the tumour, the prognosis is usually poor. Here we report a 76-year-old man in whom an extensive angiosarcoma of the scalp was treated by excision followed by wide-field radiotherapy. More than 4 years later there are no signs of local recurrence or of metastasis.


Assuntos
Hemangiossarcoma/radioterapia , Hemangiossarcoma/cirurgia , Couro Cabeludo , Neoplasias Cutâneas/radioterapia , Neoplasias Cutâneas/cirurgia , Idoso , Terapia Combinada , Hemangiossarcoma/patologia , Humanos , Masculino , Neoplasias Cutâneas/patologia , Resultado do Tratamento
10.
Ther Umsch ; 51(4): 272-7, 1994 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-7514815

RESUMO

Inoperable pulmonary malignancies can present with local stenoses of the central airways either at the time of diagnosis or later on. Depending on their localization, these obstructions cause progressive dyspnea, postobstructive atelectasis and/or pneumonia. The patient's general condition will deteriorate, and at the tracheal level life-threatening dyspnea can develop. If central airways stenosis is suspected, fiberbronchoscopy is mandatory to decide whether local endobronchial palliation is a feasible treatment modality. Usually, local palliation is combined with chemo-and/or radiotherapy. Laser resection using the Nd-YAG laser is performed for obstructions caused by endoluminal tumour growth and leads to an immediate effect after a single session. Brachytherapy means local, endobronchial irradiation with a short depth of penetration. The active probe is placed with the aid of the fiberbronchoscope. Brachytherapy can be used alone, but is often combined with an initial laser resection for the consolidation of the treatment effect. The principal of photodynamic therapy consists of photosensitization of tumour cells followed by local laser light application which leads to cell death. In selected cases this treatment can be curative. Extrinsic stenoses which are caused by external compression of the airways or by thickening of the airway walls through submucosal tumour spread must be treated by dilatation and insertion of stents (endoprostheses) to maintain airway patency. These stents--mostly self-expanding silicone or metal devices--are usually inserted with the rigid bronchoscope. Again, endobronchial and/or percutaneous radiotherapy is added to obtain longer local tumour control.


Assuntos
Neoplasias Pulmonares/radioterapia , Cuidados Paliativos/métodos , Obstrução das Vias Respiratórias/etiologia , Obstrução das Vias Respiratórias/terapia , Braquiterapia , Broncoscopia , Humanos , Terapia a Laser , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/cirurgia , Fotoquimioterapia/métodos , Stents
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA